• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Trial of sunitinib plus paclitaxel for advanced breast cancer discontinued

Article

Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer.

Pfizer is discontinuing a phase 3 study of sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for the first-line treatment of patients with advanced breast cancer. An independent data monitoring committee stated that treatment with sunitinib plus paclitaxel would not meet the primary end point of superior progression-free survival versus bevacizumab plus paclitaxel.

Other trials of sunitinib have not been affected, including a phase 3 trial evaluating sunitinib plus docetaxel versus docetaxel alone for the first-line treatment of advanced breast cancer and a phase 3 trial evaluating sunitinib plus capecitabine versus capecitabine alone for the second-line treatment of advanced breast cancer.

Pfizer announced in April that it was discontinuing a phase 3 study of sunitinib as monotherapy for the treatment of advanced breast cancer (see Sunitinib trial for advanced breast cancer discontinued).

© 2024 MJH Life Sciences

All rights reserved.